Expert Consultations: Real-World Answers

Psychodynamic Psychopharmacology – Interview

Published on April 1, 2024 Certification expiration date: April 1, 2027

Guest

Radwa Hanafy

To unlock this audio you need to become a Silver, Gold, Silver extended or Gold extended Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Interview Highlights

Utilize your therapeutic skills to identify and inquire about ambivalence during the initial assessment, enhancing the efficacy of long-term management strategies.
Encourage active patient participation in their treatment decisions, respecting their preferences for medication when feasible, to reinforce their sense of agency and improve adherence to pharmacotherapy.

Text Version

This edition of the Psychopharmacology Institute’s Expert Consultations features David Mintz, M.D., the Director of Psychiatric Education, a team leader at the Austen Riggs Center, and the former leader of the American Psychiatric Association's Psychotherapy Caucus. In this interview, we will discuss psychodynamic psychopharmacology.

Dr. Hanafy: Hello, everyone. Welcome to the Psychopharmacology Institute. We are back with another episode of Expert Consultations. I am your host, Dr. Radwa Hanafy. Today, our topic

Unlock this Expert Consultation and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.

Get Instant Access

Already have an account? Sign in

Learning Objectives:

After completing this activity, the learner will be able to:

Evaluate the impact of patient ambivalence and secondary gains on medication adherence.
Apply psychotherapeutic skills to enhance patient empowerment and medication management.
Interpret the influence of transference and countertransference on the therapeutic alliance and treatment outcomes.

Original Release Date: April 1, 2024

Expiration Date: April 1, 2027

Expert: David Mintz, M.D.

Medical Editors: Radwa Hanafy, M.D., Lorena Rodriguez, M.D.

Relevant Financial Disclosures:

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credits.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

David Mintz, M.D.